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Background: The hormone somatostatin inhibits growth hormone release from the pituitary gland and is
theoretically linked to diabetes and diabetes related complications. This study aimed to investigate the relationship
between levels of the stable somatostatin precursor, N-terminal prosomatostatin (NT-proSST), with mortality in type
2 diabetes (T2DM) patients.
Methods: In 1,326 T2DM outpatients, participating in this ZODIAC prospective cohort study, Cox proportional
hazards models were used to investigate the independent relationship between plasma NT-proSST concentrations
with all-cause and cardiovascular mortality.
Results: Median concentration of NT-proSST was 592 [IQR 450–783] pmol/L. During follow-up for 6 [3–10] years,
413 (31%) patients died, of which 176 deaths (43%) were attributable to cardiovascular causes. The age and sex
adjusted hazard ratios (HRs) for all-cause and cardiovascular mortality were 1.48 (95%CI 1.14 - 1.93) and 2.21
(95%CI 1.49 - 3.28). However, after further adjustment for cardiovascular risk factors there was no independent association
of log NT-proSST with mortality, which was almost entirely attributable to adjustment for serum creatinine. There were
no significant differences in Harrell’s C statistics to predict mortality for the models with and without NT-proSST: both
0.79 (95%CI 0.77 – 0.82) and 0.81 (95%CI 0.77 – 0.84).
Conclusions: NT-proSST is unsuitable as a biomarker for cardiovascular and all-cause mortality in stable outpatients
with T2DM.
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The hormone somatostatin plays a central role in the
inhibition of growth hormone (GH) release from the
pituitary gland [1]. Somatostatin is also secreted by
gastric and pancreatic D-cells in response to meal
ingestion through stimulation of the autonomic nervous
system [2-4]. It suppresses the release of insulin-like
growth factor-1 (IGF-1), vasoactive intestinal polypeptide,
gastrin, secretin, and pancreatic polypeptides and exerts a
range of physiological effects, such as modifying intestinal* Correspondence: p.r.van.dijk@isala.nl
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unless otherwise stated.transit time and regulating intestinal water and electrolyte
transport [1,5-8].
Somatostatin influences glucose metabolism by inhibiting
insulin, glucagon secretion and IGF-1 production [9]. In
type 2 diabetes mellitus (T2DM), somatostatin lowers
glucose concentrations by inhibiting glucagon secretion
[9,10] and abnormalities in the GH-IGF-1 axis have
been associated with increased cardiovascular risk in
T2DM [11-13].
The half-life of somatostatin in plasma is only 1–3
minutes and concentrations are generally in sub-picomolar
amounts [14,15]. The stable precursor, the N-terminal
fragment prostomatostatin 1–64 (NT-proSST), is secretedal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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approximately 1000-fold higher plasma concentrations
and is considered to reflect somatostatin concentrations
[16-18]. Recently, plasma NT-proSST concentrations were
identified as a potential marker for acute heart failure
and mortality in patients presented to an emergency
department [19]. However, the long-term predictive
capabilities of stable plasma NT-proSST concentrations in
stable outpatients with T2DM have not been studied.
Aim of the present study was to evaluate the association
and predictive capabilities of baseline plasma NT-proSST
concentrations and all-cause and cardiovascular mortality
in a prospective T2DM cohort.
Methods
Study group
The Zwolle Outpatient Diabetes Project Integrating
Available Care (ZODIAC) study was initiated in 1998, in
the Zwolle region of the Netherlands. One of the initial
study goals was studying the effects of task delegation
from physicians to specialist nurses, details have been
published previously [20,21]. As a subcategory of the
ZODIAC study the effects of several biomarkers, including
NT-proSST, on risk prediction in T2DM were planned and
blood was stored for this purpose. The ZODIAC study
cohort consisted of Dutch T2DM patients treated exclu-
sively in primary care. Patients were only excluded if they
were already treated in secondary care for their diabetes, if
they had a very short life expectancy (including patients
with active cancer) or if they were considered to have
insufficient cognitive abilities [20]. In the first year, 1,143
patients with T2DM were included, and in 2001, 546
patients with T2DM were enrolled, which resulted in
a combined study population of 1,689 patients [22].
The ZODIAC study was approved by the local medical
ethics committee (Isala, Zwolle), and all patients gave
informed consent.
Data collection and measurements
Baseline data were collected in 1998 and 2001, including
a full medical history. The diagnosis of diabetes was
based on the diagnostic criteria used in the primary care
diabetes treatment guideline of the Dutch college of
general practicioners of 1989 and 1999 (based on the
1985 World Health Organisation (WHO) and 1997
American Diabetes Association (ADA) criteria, respectively)
[23,24]. The validity of the diagnosis type 2 diabetes was
checked in the individual patient files by looking up
the glucose measurements the diagnosis was based
upon, and comparing these measurements with the
criteria for diabetes in the national guideline for each
patient [21]. Patients were considered to have a history of
CVD if they had a history of angina pectoris, myocardial
infarction, percutaneous transluminal coronary angioplasty,coronary artery bypass grafting, stroke or transient ischemic
attack. Laboratory and physical assessment data were
collected annually and included non-fasting lipid profile,
glycated hemoglobin (HbA1c), serum creatinine (sCr),
albumin-to-creatinine ratio (ACR) in a portion of urine,
and blood pressure. SCr was measured by a kinetic
colorimetric Jaffe method (Modular P Analyzer, Roche
Almere, the Netherlands), ACR was measured using
immunonephelometry (Behring Nephelometer; Mannheim,
Germany), and blood pressure was measured twice with a
Welch Allyn sphygmomanometer in the supine position
after at least 5 minutes of rest.
NT-proSST was measured in non-fasting plasma samples
collected at baseline and kept frozen at −80° Celsius until
analysis in 2010. NT-proSST was measured using an assay
in the chemiluminescence/coated tube-format (B.R.A.H.M.
S. GmbH, Hennisdorf/Berlin, Germany) [25]. For this
study, the assay used had a detection limit of 4 pmol/L;
the inter-laboratory coefficient of variation (CV) was 20%
at 18 pmol/l, 10% at 50 pmol/l, and <6% for plasma
NT-proSST concentrations above 100 pmol/L (highest
calibrator concentration used was 2500 pmol/L). The
stability of the native analyte at 22°C and 37°C was
tested in EDTA-plasma from 10 different individuals. At
22°C the analyte was stable (<10% loss of immunoreactivity)
for 72 h and at 37°C for 24 h. Samples were analysed
in duplicate. And although the samples were only
thawed for analysis, prolonged frozen storage and re-
peated (4 times) freeze-thaw cycles had no effect on
measured plasma NT-proSST concentration: in 5
EDTA-plasma samples, freezing and thawing 4 times
had no influence on the measured concentration of
proSST (mean values, 99.1% [range, 93.8%-104.3%] of
the original values).
Baseline plasma NT-proSST values could be measured
in 1,327 (79%) patients. One patient was excluded due
to extreme high values for NT-proSST (71,300 pmol/L).
Because not all patients had NT-proSST values, we
compared the baseline characteristics of subjects from
whom samples were available to those without.
Besides a higher but non-relevant difference in serum
creatinine among patients without NT-proSST mea-
surements (92 [IQR 82–104] μmol/L versus 93 [IQR
84–106] μmol/L, p = 0.02) there were no significant
baseline differences in patients with and without NT-
proSST measurements. In a separate Cox regression
analyses the association between the presence or
absence of a NT-proSST measurement and CV and all-
cause mortality in the combined cohort of 1,689 patients
was tested. For all-cause, but not for cardiovascular, mor-
tality there was an increased hazard ratio (HR) (1.3, 95%
CI 1.09 – 1.63) for patients with missing NT-proSST mea-
surements as compared to patients with NT-proSST
measurements.
van Dijk et al. BMC Endocrine Disorders  (2015) 15:19 Page 3 of 7Outcomes
Primary end-points were cardiovascular and all-cause
mortality. In 2009, vital status and cause of death
were retrieved from records maintained by the hospital
and general practitioners. Causes of death were coded ac-
cording to the International Classification of Diseases, 9th
revision (ICD-9). Cardiovascular death was defined
as death in which the principal cause of death was
cardiovascular in nature, using ICD-9 codes 390–459
[26-28].
Statistical analysis
Cox regression analyses were used to analyze the risk of
all-cause and cardiovascular mortality during follow-up.
Plasma NT-proSST concentrations were non-normally
distributed and logarithmic (log) transformation was
applied so the HR derived were expressed as an increase
in risk per doubling of baseline plasma NT-proSST
concentrations. Four models were used: (1) a crude
model, (2) a model that included age and gender and
NT-proSST, (3) a fully adjusted (duration of diabetes,
smoking (yes/no), macrovascular disease (yes/no), BMI,
systolic blood pressure, HbA1c, log SCr, cholesterol-HDL
ratio, albuminuria (yes/no)) model in which NT-proSST
was included and (4) a fully adjusted model in which
NT-proSST was not included. The additional value of
plasma NT-proSST concentrations for risk prediction of
all-cause and cardiovascular mortality was assessed with
Harrell’s C statistics. Calibration was investigated using
the Grønnesby and Borgan test, assessing the goodnessTable 1 Baseline characteristics of 1,326 patients presented a
All patients Quartile 1
NT-proSST (pmol/L) 592 [450–783] <450
N 1326 332
Deceased (N,%) 413 (31) 73 (22)
Follow-up time (years) 6 [3-10] 6 [3-10]
Female sex (N,%) 738 (56) 155 (34)
Age (years) 70 [61–76] 62 [52–72]
Smoking (%) 19.0 13
History of CVD (%) 34 26
Diabetes duration (years) 4 [2–9] 3.1 [2–8]
BMI (kg/m2) 28 [25–32] 30 [27–33]
SBP (mmHg) 150 [140–170] 150 [135–162]
HbA1c (%) 7.0 [6.3 - 8.0] 7.1 [6.3 - 8.3]
HbA1c (mmol/mol)
Serum creatinine (μmol/L) 92 [82–104] 86 [77–94]
Cholesterol:HDL ratio 4.8 [3.9 - 6.0] 4.8 [3.9 - 5.7]
Albuminuria present (N,%) 515 (39) 129 (39)
Values are depicted as n (%), mean (SD) or median [IQR]. Abbreviations: BMI body m
CI confidence interval, CVD cardiovascular diseases, HDL high-density lipoprotein, IQof fit [29]. Statistical analyses were performed using
SPSS (IBM SPSS Statistics for Windows, Version 20.0.
Armonk, NY: IBM Corp.) and STATA version 12
(Stata Corp., College Station, TX: StataCorp LP). A
two-sided p < 0.05 was considered significant.
Results
Baseline characteristics of the study population per quartile
are presented in Table 1. The baseline median plasma
NT-proSST concentration in 1,326 patients was 591
[IQR 450–783] pmol/L. Concentrations were significantly
higher in women than in men (618 [IQR 474–803] pmol/L
versus 558 [IQR 430–746] pmol/L respectively, p < 0.001).
During a median follow-up for 6 [IQR 3–10] years,
413 (31%) patients died, of which 176 (43%) died
from cardiovascular causes. Median baseline plasma
NT-proSST concentration of patients that were alive
(558 [IQR 435–728] pmol/L) was significantly lower than
that of patients that died (683 [IQR 514–894] pmol/L)
and those that died from cardiovascular causes (743
[IQR 546–993] pmol/L) (both p < 0.001) (Figure 1).
In univariate Cox regression analyses the log NT-proSST
was significantly associated with all-cause (HR 2.80, 95%
CI 2.17 - 3.60) and cardiovascular mortality (HR 3.86, 95%
CI 2.64 - 5.62). The corresponding age and gender
adjusted HRs were 2.21 (95% CI 1.49 - 3.28) and 1.48
(95% CI 1.14 - 1.93). In the fully adjusted model, the
association of log NT-proSST with all-cause and cardio-
vascular mortality was no longer significant (HRs 1.09
(95% CI 0.81-1.46) and 1.07 (95% CI 0.69-1.68)).s quartiles NT-proSST concentration
Quartile 2 Quartile 3 Quartile 4 P-value
450-590 590-780 >780
330 332 332
74 (22) 115 (35) 151 (46)
9 [3-10] 7 [3-10] 5 [3-10]
182 (55) 198 (60) 203 (61) <0.01
65 [58–72] 69 [61–77] 73 [65–78] <0.01
16 13 13 0.28
33 37 42 <0.01
4 [2–9] 5 [2–10] 5 [2–10] <0.01
29 [26–32] 29 [25–32] 28 [25–30] <0.01
150 [135–170] 150 [140–170] 150 [135–170] 0.29
7.0 [6.2 – 8.1] 7.0 [6.4 - 8.0] 7.0 [6.3 - 8.0] 0.83
89 [80–100] 93 [84–105] 102 [89–199] <0.01
4.8 [4.0 - 5.7] 4.7 [3.9 - 6.1] 4.8 [3.8 - 5.9] 0.68
106 (32) 130 (39) 150 (45) <0.01
ass index, CVD cardiovascular disease, SBP systolic blood pressure,
R interquartile range, NT-proSST N-Terminal prosomatostatin.
Year 2 4 6 8 10
Quartile 1 17/315 32/192 52/170 66/152 71/111
Quartile 2 16/314 34/200 51/180 60/169 73/120
Quartile 3 19/313 45/209 74/178 93/157 115/100
Quartile 4 36/296 78/176 109/144 135/115 149/78
Year 2 4 6 8 10
Quartile 1 9/315 18/186 26/170 29/152 30/111
Quartile 2 8/315 14/201 18/180 21/19 25/120
Quartile 3 8/313 18/209 28/178 34/157 43/100
Quartile 4 21/296 47/177 65/144 74/116 77/78
Figure 1 Kaplan Meier survival curves for the associations between quartiles of PSS and all-cause mortality (upper panel) and cardiovascular
mortality (lower panel). The green line shows quartile 1, the blue line quartile 2, the yellow line quartile 5 and the purple line quartile 4.
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model was built; the introduction of sCr to the model re-
sulted in the disappearance of an independent relationship
between log NT-proSST and all-cause and cardiovascular
mortality. Furthermore, the fully adjusted model for
all-cause mortality without sCr had a significantly
lower goodness of fit, X2 374 (df 11) versus 391 (df 12)
(p < 0.001), as compared to the complete model.The Harrell’s C statistics in Table 2 show that the more
potential confounders and cardiovascular risk factors
adjusted for, the better the model predicted cardiovascular
and all-cause mortality. Harrell’s C-values were not
different for models 3 and 4, both for all cause and cardio-
vascular mortality, indicating that plasma NT-proSST
concentrations have no additional value on top of well-
known risk factors. The Grønnesby and Borgan p-values
Table 2 Hazard ratio’s and additional value of baseline log2 NT-proSST concentrations in risk prediction compared to
established cardiovascular risk markers
Model 1 Model 2 Model 3 Model 4
All-cause mortality
Hazard ratio (95%CI) 2.80 (2.17-3.60) 1.48 (1.14-1.93) 1.09 (0.81-1.46) NA
Harrel’s C (95% CI) 0.62 (0.59-0.65) 0.77 (0.75-0.80) 0.79 (0.77-0.82) 0.79 (0.77-0.82)
Grønnesby and Borgan test p-value 0.60 0.11 0.51 0.32
Cardiovascular mortality
Hazard ratio (95%CI) 3.86 (2.64-5.62) 2.21 (1.49-3.28) 1.07 (0.69-1.68) NA
Harrel’s C (95% CI) 0.65 (0.60-0.70) 0.76 (0.72-0.80) 0.81 (0.77-0.84) 0.81 (0.77-0.84)
Grønnesby and Borgan test p-value 0.16 0.03 0.06 0.06
Model 1: crude.
Model 2: as model 1 and also adjusted for age and sex.
Model 3: as model 2 and also adjusted for duration of diabetes, smoking (yes/no), macrovascular disease (yes/no), BMI, SBP, HbA1c, log sCr, cholesterol-HDL ratio,
albuminuria (yes/no) and NT-proSST.
Model 4: model 3 without NT-proSST.
Abbreviations: BMI body mass index, CI confidence interval, HDL high-density lipoprotein, HR Hazard ratio, SBP systolic blood pressure, sCr serum creatinine.
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cardiovascular mortality, all models were well calibrated.
The Schoenfeld residuals showed no substantial deviations,
supporting the assumption for proportional hazards.
Discussion
This is the first study to investigate the relation between
plasma NT-proSST concentrations and mortality in
outpatients with T2DM after long-term follow-up.
The age- and gender corrected plasma NT-proSSTconcen-
trations were associated with all-cause and cardiovascular
mortality. After adjustment for all classic risk factors,
plasma NT-proSST concentrations were not associated
with all-cause and cardiovascular mortality and had no
added benefit with regard to risk prediction.
Adding plasma NT-proSST concentrations to a model
with potential confounders and well-known cardiovascular
risk factors for mortality did not improve the Harrel’s C
statistic compared to the fully adjusted model without
plasma NT-proSST concentrations, indicating a lack of
benefit in risk prediction when adding NT-proSST. The
absence of a relationship is most likely caused by a
true lack of additional predictive capabilities of plasma
NT-proSST concentrations, although we cannot exclude
that the absence of a relationship was caused by the
relatively high initial predictive capability for the
model without plasma NT-proSST concentrations or
mutual correlations between plasma NT-proSST concen-
trations with 9 additional traditional cardiovascular risk
markers. To explore this in more detail, we per-
formed a post-hoc step-wise Cox model analysis in
which the independent relationship between plasma
NT-proSST concentrations and mortality disappeared
after introduction of sCr. Since somatostatin is known
to influence renal function and the administration of
somatostatin analogues inhibit the GH-IGF-1 relateddecline in renal function in T2DM, increased plasma
NT-proSST concentrations may reflect a compensatory
increase in somatostatin in order to prevent progression
of renal decline among patients with T2DM [30-32].
Alternatively, a decreased renal clearance of NT-proSST
from the circulation could also be hypothesized in this
T2DM population. Whatever putative benefit an increase
in plasma NT-proSST concentrations might provide for
renoprotection, there was no accompanying mortality
benefit.
Some other limitations should be mentioned. Due to the
exclusion of 21% patients with missing plasma NT-proSST
concentrations, selection bias could have been introduced.
For this reason, we calculated the HR for missing values on
NT-proSST for total mortality (HR 1.33, 95% CI 1.08–1.63,
in a crude model), an outcome that suggests an under-
estimation of the relationship observed. Furthermore, we
cannot exclude the presence of difference in outcomes
between patients who received task delegation care
during the first 3 years of the ZODIAC study and patients
who did not. Unfortunately, data on relevant comorbidity
besides cardiovascular diseases are unknown. As plasma
NT-proSST concentration was only measured once,
correction for potential fluctuations in NT-proSST
concentrations, in particular related to food intake,
was not possible [3].
Nevertheless, the present study adds to the current
literature by describing for the first time the predictive
capabilities of NT-proSST in a large cohort of patients
with T2DM with sufficient follow-up. Based on these re-
sults, NT-proSST appears to be no suitable biomarker for
cardiovascular an all-cause mortality prediction in patients
with T2DM. However, these results do not exclude a role
for NT-proSST a potential marker for short term risk pre-
diction and further research should focus on the use of
NT-proSST as a biomarker in specific areas such as
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endocrine and gastro-intestinal processes [3,19,33,34].
Conclusion
After correction for a set of well-known risk factors, high
plasma NT-proSST concentrations were not independently
associated with increased all-cause and cardiovascular
mortality in patients with T2DM. The plasma NT-proSST
concentration does not appear to be suitable as a bio-
marker for the prediction of mortality in stable outpatient
with T2DM.
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